Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Anatomic Stage II Breast Cancer AJCC v8 × Immunoglobulin G × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Pancreatic Neoplasms 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Hydronephrosis 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

tremelimumab 1 durvalumab 1 Immunoglobulin G 1 Disulfides 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03132467 2024-06-05

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Completed

16 enrolled 8 charts

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon ⚡